Paradigm boosts funding to carry Phase 3 trial through key interim data

An update from Paradigm Biopharmaceuticals ( (AU:PAR) ) is now available.

Paradigm Biopharmaceuticals has completed a significantly upsized A$14 million institutional placement, above the initial A$8 million target, and launched a share purchase plan of up to A$2 million to allow eligible shareholders to participate on similar terms. The raise, which includes an attaching option structure, bolsters Paradigm’s cash to about A$45 million, extending its funding runway through the interim analysis of its Phase 3 PARA_OA_012 trial expected in Q3 2026 and supporting preparations for a potential NDA submission, reducing reliance on its existing convertible note facility and underpinning a key value inflection period for investors.

The most recent analyst rating on (AU:PAR) stock is a Buy with a A$0.65 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.

More about Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals Ltd is a late-stage drug development company listed on the ASX that focuses on delivering new therapies to address unmet medical needs. The company is currently advancing a global Phase 3 clinical program, targeting conditions where existing treatments are inadequate and positioning itself within the specialty biopharmaceuticals segment.

YTD Price Performance: -33.82%

Average Trading Volume: 1,214,546

Technical Sentiment Signal: Sell

Current Market Cap: A$101.6M

See more insights into PAR stock on TipRanks’ Stock Analysis page.